Mazen Animal Health. Jennifer Filbey, Ph.D. CEO November 7, 2018

Transcription

1 Mazen Animal Health Jennifer Filbey, Ph.D. CEO November 7, 2018

2 Positive Disruption is our Mission First in Class Edible Vaccines Feed Through Vaccines For Production Animals

3 Key Unmet Needs in Production Animals Producers need: Increased biosecurity Increased production margins Decreased antibiotics usage Improved disease prevention Mazen proposes: Subunit vaccines (ARS) Cost effective Replaces antibiotics Efficacy demonstrated Coccidiosis causes $3.5B in annual losses

4 Mazen & USDA-ARS are Joining Forces to Provide a Cost- Effective Vaccine Solution to Coccidiosis Coccidiosis is currently managed using a cyclical approach of spray or water-based live vaccines alternated with ionophore antibiotics and other anti-coccidiosis measures We need a safer, more efficacious, easier to use and cost-effective approach ARS has sub-unit antigens shown to be effective against Eimeria infections EF-1alpha 3-1e/profilin Gam82 Mazen can express sub-unit vaccines in maize grain creating edible vaccines Can be dosed with feed Cost effective Can t replicate Lillehoj, H. S., Ding, X., Quiroz, M. A., Bevensee, E., and Lillehoj, E. P. (2005) Avian diseases 49, Lin, R.-Q., Lillehoj, H. S., Lee, S. K., Oh, S., Panebra, A., and Lillehoj, E. P. (2017) Veterinary parasitology 243, Jang, S. I., Lillehoj, H. S., Lee, S. H., Lee, K. W., Park, M. S., Cha, S.-R., Lillehoj, E. P., Subramanian, B. M., Sriraman, R., and Srinivasan, V. (2010) Vaccine 28,

5 Clear Defensible & Competitive Advantages Over 15 issued and pending patents Process Use Enhanced immunogenicity Promoters Ex: 9,944,937 Patents pending for PEDV and Valley Fever Strong IP estate in the U.S. Patents pending related to three antigens from USDA-ARS

6 Global Vaccine Market is over $7B Revenue projected to reach $300M by 2026 with US & International Sales 350,000,000 Porcine Epidemic Diarrhea Virus Valley fever Avian Coccidiosis 300,000, ,000, ,000, ,000, ,000,000 50,000,000 Feline - Rabies Canine - Rabies Fish Vaccine - Trout Feline - Panleuk, Calic, Rhino Canine - Parvo, Dist, Hep Fish Vaccine - Salmon Poultry - Coccidiosis PCV-2 - Swine/Piglet PEDV - Swine/Piglet Valley Fever - Canine EBIT (50,000,000)

7 TEAM Mazen Experienced Leadership Team Animal Health, Technical & Commercial Expertise World leader in protein expression in maize grain CEO of ABI 30 years of biotech experience Entrepreneur focused on commercialization of new technologies President of NPI Nektar, Nobex, Hoechst Candidate Identified Animal health, feed ingredients & production animal marketing Elanco Bayer John Howard, PhD Founder, CSO Jenny Filbey, PhD Founder, CEO Kerryann Kocher Marketing Regulatory, business development, tech operations Expedite Animal Health Candidate Identified Finance & corporate development Public & private company experience Tom Overbay, DVM Development CPA CFO CPA CFO

8 TEAM Experienced Board Animal Health, Technical & Commercial Expertise Kelly Lechtenberg, DVM President of Midwest Veterinary Services & the Veterinary and Biomedical Research Center Infectious Disease Model Specialist Food Animal Production Consultant Terry Speizer, MBA Serial entrepreneur Morro View Winery Domaine Alfred Winery Electec, Flextec Ronan Molloy, JD President, Innovation Stockyard Zoetis, Synbiotics, Primus Entrepreneur focused on commercialization of new technologies President of NPI Nektar, Nobex, Hoechst World leader in protein expression in maize grain CEO of ABI 30 years of biotech experience Jenny Filbey, Ph.D. John Howard, Ph.D.

9 PoC Provides Value Creation Antigen Production PoC in target animal Key Risk Reduction Step Implementation Master Seed Working Seed Efficacy Pre-licensing Serials Safety

10 Equity Financing Round is Open Targeting a $20M Raise Fast to Market for First-in-Class Edible Vaccine Cost effective Safer to deliver More efficacious Global reach 10 + x multiple on investment Disrupt animal disease prevention globally

11 Jennifer Filbey, Ph.D. CEO

12